Familial pterygium of the conjunctiva

Summary

Familial pterygium of the conjunctiva (MONDO:0008337) is a disease and 3 clinical trials. Top therapeutic interventions include bevacizumab and fluorometholone. A subtype of pterygium — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Phenotypes (HPO): 3
• Clinical trials: 3

Clinical features

Signs & symptoms

Clinical features (HPO)

3 HPO clinical features (Orphanet curated; top 3 by frequency):

HPO ID	Term	Frequency
HP:0000478	Abnormality of the eye	Very frequent (80-99%)
HP:0000504	Abnormality of vision	Very frequent (80-99%)
HP:0007759	Opacification of the corneal stroma	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	familial pterygium of the conjunctiva
Mondo ID	MONDO:0008337
MeSH	C566740
OMIM	178000
Orphanet	2989
UMLS	C4274782
MedGen	896736
GARD	0004569
Is cancer (heuristic)	no

Also known as: pterygium of the conjunctiva and cornea

Data availability: 2 cell lines.

Disease family

This is a subtype of pterygium. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › conjunctival disorder › conjunctival tumor › benign conjunctival neoplasm › pterygium › familial pterygium of the conjunctiva

Related subtypes (2): double pterygium, conjunctival pterygium

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07343011	Not specified	RECRUITING	Conjunctival Transpositional Surgery for Primary Pterygium
NCT01288404	Not specified	COMPLETED	Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
NCT06944132	Not specified	COMPLETED	CsA vs MMC for Preventing Pterygium Recurrence

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
FLUOROMETHOLONE	4	1
CHEMBL1716015	0	1